Template:Mefloquine: Difference between revisions
Created page with "__NOTOC__ {{Mefloquine}} {{CMG}}; {{AE}} {{chetan}} ==Overview== ==Category== Antimalarial ==US Brand Names== MEFLOQUINE HYDROCHLORIDE<sup>®</sup> ==FDA Package Insert== '..." |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
'''Mefloquine''' hydrochloride (Lariam, Mephaquin or Mefliam) is an orally administered [[antimalarial drug|medication]] used in the prevention and treatment of [[malaria]]. Mefloquine was developed in the 1970s at the [[United States Department of Defense]]'s [[Walter Reed Army Institute of Research]] as a synthetic analogue of [[quinine]]. The brand name drug, Lariam, is manufactured by the Swiss company [[Hoffmann–La Roche]]. In August 2009, Roche stopped marketing Lariam in the United States. Generic mefloquine from other manufacturers is still widely available. Rare but serious neuropsychiatric problems have been associated with its use.<ref name=":0">Thomas, Katie. "F. D. A. Strengthens Warnings on Lariam, an Anti-Malarial Drug." ''The New York Times''. July 29, 2013.</ref> | |||
==Category== | ==Category== | ||
Antimalarial | Antimalarial | ||
Revision as of 00:45, 8 January 2014
Template loop detected: Template:Mefloquine
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Overview
Mefloquine hydrochloride (Lariam, Mephaquin or Mefliam) is an orally administered medication used in the prevention and treatment of malaria. Mefloquine was developed in the 1970s at the United States Department of Defense's Walter Reed Army Institute of Research as a synthetic analogue of quinine. The brand name drug, Lariam, is manufactured by the Swiss company Hoffmann–La Roche. In August 2009, Roche stopped marketing Lariam in the United States. Generic mefloquine from other manufacturers is still widely available. Rare but serious neuropsychiatric problems have been associated with its use.[1]
Category
Antimalarial
US Brand Names
MEFLOQUINE HYDROCHLORIDE®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
The exact mechanism of action is uncertain. However, it is proposed to share a similar mechanism of action with chloroquine, which is inhibition of heme polymerase.
References
- ↑ Thomas, Katie. "F. D. A. Strengthens Warnings on Lariam, an Anti-Malarial Drug." The New York Times. July 29, 2013.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [4]
Overview
Mefloquine hydrochloride (Lariam, Mephaquin or Mefliam) is an orally administered medication used in the prevention and treatment of malaria. Mefloquine was developed in the 1970s at the United States Department of Defense's Walter Reed Army Institute of Research as a synthetic analogue of quinine. The brand name drug, Lariam, is manufactured by the Swiss company Hoffmann–La Roche. In August 2009, Roche stopped marketing Lariam in the United States. Generic mefloquine from other manufacturers is still widely available. Rare but serious neuropsychiatric problems have been associated with its use.[1]
Category
Antimalarial
US Brand Names
MEFLOQUINE HYDROCHLORIDE®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
The exact mechanism of action is uncertain. However, it is proposed to share a similar mechanism of action with chloroquine, which is inhibition of heme polymerase.
References
- ↑ Thomas, Katie. "F. D. A. Strengthens Warnings on Lariam, an Anti-Malarial Drug." The New York Times. July 29, 2013.